Risk factors
Fractyl Health (GUTS) risk factors
Item 1A of every Fractyl Health, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors101 risks8 new14 dropped24 reworded
Going-concern pressure intensified: 2025 net loss rose to $141.0 million, accumulated deficit reached $556.3 million, and substantial doubt was identified.
Filed Mar 24, 2026 - FY2024 10-K risk factors107 risks
Fractyl Health faces high concentration risk on its lead product Revita and Rejuva gene therapy candidates, ongoing cash burn with net losses, and strict regulatory and clinical hurdles.
Filed Mar 03, 2025